Evidence map›Paper›PMID 29923314›Full record

Trial reportCNS neuroscience & therapeutics2019

A cholecystokinin B receptor antagonist and cocaine interaction, phase I study.

Ahmed Elkashef, James Robert Brašić, Louis R Cantelina, Roberta Kahn, Nora Chiang, Weiguo Ye, Yun Zhou, Jurij Mojsiak, Kimberly R Warren, Andrew Crabb and 3 more

Open access · bronzeAbstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in CNS neuroscience & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Ahmed ElkashefMedications Development Division, The National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-5866-8498
James Robert BrašićSection of High Resolution Brain Positron Emission Tomography Imaging, Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Louis R CantelinaDivision of Clinical Pharmacology and Medical Toxicology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Roberta KahnMedications Development Division, The National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.
Nora ChiangMedications Development Division, The National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.
Weiguo YeSection of High Resolution Brain Positron Emission Tomography Imaging, Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Yun ZhouSection of High Resolution Brain Positron Emission Tomography Imaging, Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Jurij MojsiakMedications Development Division, The National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.
Kimberly R WarrenDepartment of Psychology, Morgan State University, Baltimore, MD, USA.
Andrew CrabbSection of High Resolution Brain Positron Emission Tomography Imaging, Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
John HiltonSection of High Resolution Brain Positron Emission Tomography Imaging, Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Dean F WongSection of High Resolution Brain Positron Emission Tomography Imaging, Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Frank VocciMedications Development Division, The National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.
Johns Hopkins University · USNational Institutes of Health · USMorgan State University · USUniformed Services University of the Health Sciences · USUniversity of Maryland, Baltimore · US

Funding

IMAGING RESEARCH IN NEUROPSYCHIATRY AND DRUG ABUSEK24DA000412 · NIDA · JOHNS HOPKINS UNIVERSITY · PI WONG, DEAN FOSTER · 2000 to 2009
$1.5M
Intramural NIH HHS Z99 DA999999NIDA NIH HHS K24 DA000412
6 · The paper itself

Abstract

aimsRPR 102681, a cholecystokinin-B antagonist, increased dopamine (DA) release and reduced cocaine self-administration in animals. This pilot study sought to assess the safety and pharmacokinetics (PK) of co-administration of RPR 102681 and cocaine, and to confirm the DA release mechanism of RPR 102681.

methodsSixteen cocaine-dependent participants were randomized to either placebo or RPR102681 at 3 ascending doses; cocaine was co-administered at steady state of RPR 102681. [

resultsRPR 102681 was well tolerated, and safe to co-administer with cocaine. RPR 102681 did not alter the PK of either cocaine or its metabolite benzoylecgonine and showed no intrinsic abuse liability. There was a trend toward reduction of cocaine craving scores. In contrast to animal studies, RPR 102681 significantly increased the binding potential of [

conclusionOverall, this pilot study suggests that RPR 102681 would be unlikely candidate, as an agonist medication for the treatment for cocaine addiction but worth investigating further for possible role in reducing craving.

Indexed as

AcetamidesAdultBrainCentral Nervous System AgentsCocaineCocaine-Related DisordersCravingDopamineDopamine Uptake InhibitorsDose-Response Relationship, DrugDouble-Blind MethodDrug InteractionsFemaleHumansMaleMiddle AgedAcetamidesCentral Nervous System AgentsCocaineDopamineDopamine Uptake InhibitorsPhenylurea CompoundsRacloprideRadiopharmaceuticalsReceptor, Cholecystokinin BRP 72540addictioncravingdopaminepositron emission tomographyRPR 102681

Identifiers

PMID29923314
PMCPMC6309275
OpenAlexW2809271913

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.